BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Radi Medical Systems AB Release: JACC Identifies DEFER with 5-year Outcomes as Landmark Trial


3/10/2008 7:49:15 AM

UPPSALA, Sweden and WILMINGTON, Mass., March 7 /PRNewswire/ -- The Journal of the American College of Cardiology has recognized the five-year follow-up results of the DEFER (Deferral Versus Performance of PTCA in Patients Without Documented Ischemia) as one of the studies that had the greatest impact on cardiology in 2007, according to an article entitled "Highlights of the Year in JACC" by Anthony N. DeMaria, MD, et al. (JACC Vol. 51, No. 4, 2008 January 29, 2008:490-512)

Initially published in the May 29, 2007, issue of the peer-reviewed journal, DEFER concluded that patients treated based on fractional flow reserve (FFR) results had achieved long-term outcomes equal, or superior, to patients who underwent stenting solely based on angiographic evidence. The study's investigators measured FFR using PressureWire(R), a diagnostic tool developed by Radi Medical Systems AB.

Dr. Nico Pijls, the study's principal investigator, said, "From the DEFER study and other recent publications, it has become clear that the key issue in deciding which lesions should be stented is knowledge about whether a stenosis is responsible for ischemia. We are glad that JACC has recognized this study that demonstrates the importance of FFR and its role in interventional cardiology."

FFR expresses maximum achievable blood flow in a coronary artery with abnormal stenosis as a fraction of maximum blood flow in the absence of a stenosis. FFR is 100% specific in identifying which lesions are actually causing the flow restriction and may be treated.

"The DEFER data was, and continues to be, an important topic of discussion among cardiologists," said Jim Archetto, Chief Operating Officer of Radi Medical Systems, Inc. "There is a lot of uncertainty in interventional cardiology when it comes to determining whether or not a stent is necessary. Measuring FFR is the only way physicians can determine with precision that a suspect lesion requires treatment."

As an adjunct to DEFER, authors have designed a new 1000 patient study, Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) (American Heart Journal Volume 154, Number 4). The objective of this groundbreaking, multicenter, randomized clinical trial is to compare angiographic guidance versus fractional flow reserve (FFR) to determine which coronary lesions to stent in patients with multivessel coronary disease.

The primary end point of the study is a composite of major adverse cardiac events, including death, myocardial infarction, and repeat coronary revascularization, at 1 year.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit www.radi.se.

david.schull@russopartnersllc.comian.stone@russopartnersllc.comjim.archetto@radi.se

CONTACT: David Schull, david.schull@russopartnersllc.com, or Ian Stone,
ian.stone@russopartnersllc.com, both of Russo Partners LLC,
+1-212-845-4271, for Radi; or Jim Archetto of Radi Medical Systems Inc.,
+1-877-337-7234, Ext. 812, jim.archetto@radi.se

Web site: http://www.radi.se/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES